Aptevo Therapeutics Inc Stock Price, News & Analysis

Aptevo Therapeutics reported its financial results for Q3 2021, highlighting a cash position of $53.4 million and a net loss of $7.0 million, or $1.43 per share. Royalty revenue from Pfizer's RUXIENCE was $3.1 million. The company initiated the expansion phase of its Phase 1B clinical trial for APVO436 in acute myeloid leukemia. Research and development expenses decreased slightly to $4.4 million, while general and administrative expenses rose to $3.5 million. Aptevo continues to progress with the ADAPTIR and ADAPTIR-FLEX platforms in various industry forums.

Alligator Bioscience and Aptevo Therapeutics announced the presentation of preclinical data for ALG.APV-527, a bispecific antibody targeting 4-1BB and tumor antigen 5T4, at the SITC Annual Meeting on November 13, 2021. The data suggest potential efficacy in eliciting antitumor responses with minimized systemic activation. The poster outlines a dual expression mechanism supporting clinical protocols and demonstrates enhanced immune-mediated tumor cell killing. This advancement supports the molecule's progression to a phase I clinical trial, indicating a promising future for treating 5T4-expressing solid tumors.

Aptevo Therapeutics (APVO) presented promising preclinical data on its bispecific antibody APVO603 at the SITC 2021 Annual Meeting. The data highlights APVO603's effectiveness in enhancing tumor cell lysis when combined with a bispecific T-cell engager. This dual 4-1BB and OX40 targeting approach may improve T cell responses against solid tumors while minimizing regulatory T cell suppression. CEO Marvin White expressed optimism about the results and the ongoing development of APVO603, which aims to deliver robust anti-tumor responses.

Aptevo Therapeutics (NASDAQ:APVO) will present clinical data on its leukemia drug candidate APVO436 at the 2nd Virtual Congress on Controversies in Leukemias on October 28-29, 2021. The presentation highlights findings from a Phase 1B clinical study involving 46 adult patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The data shows that APVO436 is generally well-tolerated and displays preliminary efficacy, underscoring its potential as a therapeutic option for patients in urgent need.

Aptevo Therapeutics Inc. (NASDAQ:APVO) announced that its research on APVO436, a bispecific antibody for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), has been published in Cancers. The study indicated that only 21.7% of 46 patients treated with APVO436 developed cytokine release syndrome (CRS), a common side effect of such therapies. The severe CRS cases were low at 8.7%. This promising data highlights APVO436 as a potential new treatment option for patients with these challenging blood cancers.

Aptevo Therapeutics announced that its lead candidate, APVO436, showed clinical activity and an acceptable safety profile for treating adults with myelodysplastic syndrome (MDS). The article published in Frontiers in Aging discusses the potential of bispecific antibodies to target both MDS clones and immunosuppressive cells, crucial for high-risk MDS patients. In a study, APVO436 induced complete remissions in 3 out of 6 evaluable high-risk MDS patients, suggesting its promise as a new anti-MDS drug candidate.

Aptevo Therapeutics announced promising results from a Phase 1 clinical study of its lead drug candidate, APVO436, for patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The study involved 46 adult patients, with 27.5% achieving favorable responses, including complete remissions. APVO436 demonstrated a favorable safety profile, with manageable adverse events primarily involving infusion reactions. The median survival for responding patients exceeded 300 days, compared to 100 days for others. These findings support further clinical development of APVO436 as a potential new treatment option.

Aptevo Therapeutics (APVO) reported financial results for Q2 2021, highlighting a net loss of $7.9 million or $1.75 per share, compared to a loss of $6.8 million or $2.10 per share in Q2 2020. Cash and cash equivalents totaled $61.7 million, with a runway through Q3 2022. The company advanced its Phase 1 trial for APVO436 in treating acute myeloid leukemia, showing promising safety and preliminary efficacy. Aptevo was also added to the Russell Microcap Index, reflecting growth and increased visibility in the market.

Aptevo Therapeutics (NASDAQ:APVO), a clinical-stage biotechnology company, announced that Dr. Jane Gross will speak at the Cambridge Health Institute PEGS Virtual Conference from July 19-22, 2021. Her presentation, titled Generating Immuno-Modulatory Bispecific Therapeutic Candidates for the Treatment of Hematologic and Solid Tumors, is scheduled for July 19 at 11:25 AM ET. Dr. Gross will also participate in a panel discussion on bispecific antibodies versus CAR T therapies at noon on the same day. Aptevo aims to leverage its ADAPTIR technologies for novel cancer treatments.